Wall Street Analysts Believe Kiniksa Pharmaceuticals Could Rally 30.11 percent Heres is How to Trade

KNSA Stock  USD 22.04  0.24  1.10%   
About 52% of Kiniksa Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that many traders are impartial. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
The consensus price target hints at a 30.1 percent upside potential for Kiniksa Pharmaceuticals . While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read at zacks.com
zacks News
  

Kiniksa Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Kiniksa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Kiniksa Pharmaceuticals Fundamental Analysis

We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Beta

Beta Comparative Analysis

Kiniksa Pharmaceuticals is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Kiniksa Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Kiniksa Pharmaceuticals Related Equities

VTYXVentyx Biosciences   23.30   
0%
100.0%
REPLReplimune   8.45   
0%
36.0%
GOSSGossamer Bio   6.06   
0%
26.0%
CHRSCoherus BioSciences   5.79   
0%
24.0%
LYRALyra Therapeutics   5.26   
0%
22.0%
BOLTBolt Biotherapeutics   5.00   
0%
21.0%
COGTCogent Biosciences   4.79   
0%
20.0%
NVCTNuvectis Pharma   4.04   
0%
17.0%
CGEMCullinan Oncology   1.83   
0%
7.0%
ACLXArcellx   1.73   
0%
7.0%
DAWNDay One   0.89   
0%
3.0%
NUVLNuvalent   0.71   
0%
3.0%
GPCRStructure Therapeutics   0.79   
3.0%
0%
PHATPhathom Pharmaceuticals   1.32   
5.0%
0%
SPROSpero Therapeutics   1.74   
7.0%
0%
KURAKura Oncology   1.92   
8.0%
0%
KRONKronos Bio   2.25   
9.0%
0%
LRMRLarimar Therapeutics   2.37   
10.0%
0%

Complementary Tools for Kiniksa Stock analysis

When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences